Subscribe To

Price Alert Latest News Economic Calendar News

APGE / Apogee Therapeutics to raise up to $263.1M in IPO

Apogee Therapeutics Inc will offer 15.625 million of its common shares in an initial public offering (IPO) that is expected to be priced between $15 and $17 per share, according to a US Securities and Exchange Commission (SEC) filing. The stock offering, which would value the company at as much as $774.5 million, is expected to net Apogee proceeds of between $228.2 million and $263.1 million, depending on whether the underwriters exercise in full their option to purchase additional shares. Read More

Demo Live Account See Partner Details

Content Topics

Apogee

Therapeutics

Raise

263 1m

Stock

APGE

Posted: Jul 11 2023, 09:31

Author Name: Proactive Investors

APGE News

By Seeking Alpha
August 22, 2023

Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing

Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending pos

By Seeking Alpha
July 15, 2023

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

Following the Independence Day lull, the July IPO market warmed up with two sizable biotechs, joined by two blank check companies. Surf Air Mobility d

By Proactive Investors
July 11, 2023

Apogee Therapeutics to raise up to $263.1M in IPO

Apogee Therapeutics Inc will offer 15.625 million of its common shares in an initial public offering (IPO) that is expected to be priced between $15 a

By Seeking Alpha
July 10, 2023

IPO Update: Apogee Therapeutics Proposes Terms For $250 Million IPO

Apogee Therapeutics, Inc. has filed proposed terms for a $250 million IPO. The firm is developing drug treatment candidates for atopic dermatitis, COP

By Market Watch
July 10, 2023

Apogee Therapeutics sets IPO terms, to be valued at up to $774.5 mln

Apogee Therapeutics Inc. APGE, has set terms for its initial public offering, as the Massachusetts-based biotechnology company developing treatments f

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.